Colinz Laboratories Ltd

As of 14-Nov, Colinz Laboratories Ltd is currently priced at 42.74, reflecting a recent increase and strong performance with a total return of 7.49% over four days. Despite this, the stock remains down 38.73% year-to-date, indicating long-term struggles compared to the Sensex's gain of 8.22%.

As of 06-Nov, Colinz Laboratories Ltd's stock price is Rs 39.81, down 9.99%, significantly underperforming its sector and the broader market. The stock has seen a notable decline in investor participation and has consistently traded below key moving averages, indicating negative sentiment.

Colinz Laboratories' latest Q2 FY26 results are concerning, showing an 11.46% decline in net sales and compressed operating margins, despite a slight sequential improvement in net profit. Overall, the company faces significant challenges with deteriorating revenue trends and questions about earnings quality.

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

As of 03-Nov, Colinz Laboratories Ltd is seeing a price increase to Rs 44.90, up 8.11%, with significant intraday gains and increased investor participation. Despite a year-to-date decline, the stock has outperformed the Sensex recently, indicating positive investor sentiment.

As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55 and an EV to EBIT of 14.07, but has underperformed significantly with a year-to-date return of -40.47%, contrasting with a 7.42% gain in the Sensex.

As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55, an EV to EBITDA ratio of 14.07, and a ROE of 5.07%, but has underperformed with a year-to-date return of -40.47% compared to the Sensex's 7.42%.

As of October 31, 2025, Colinz Labs is fairly valued with a PE ratio of 39.55, an EV to EBITDA of 14.07, and a ROCE of 10.08%, positioning it in the middle of its industry valuation spectrum despite a year-to-date stock decline of 40.47%.

As of October 29, 2025, Colinz Labs is considered overvalued with a PE ratio of 39.04, an EV to EBIT of 13.83, and a low ROE of 5.07%, significantly higher than its peers and underperforming the Sensex with a year-to-date return of -41.23%.

As of October 28, 2025, Colinz Labs is fairly valued with a PE Ratio of 37.43, an EV to EBIT of 13.05, and a ROCE of 10.08%, showing potential undervaluation in growth despite a year-to-date return of -43.66%.

As of 28-Oct, Colinz Laboratories Ltd's stock price has declined to Rs 39.30, down 9.45%, following a trend reversal after four days of gains. The stock is underperforming significantly compared to the Sensex and is trading below all major moving averages, indicating a bearish trend.

As of 27-Oct, Colinz Laboratories Ltd's stock price is Rs 43.40, up 2.48% recently, but it has a year-to-date decline of 37.79%. While it shows short-term positive momentum, its long-term performance and decreasing investor participation raise concerns.

As of October 23, 2025, Colinz Labs is overvalued with a PE ratio of 40.00 and a year-to-date decline of 39.79%, significantly underperforming compared to its peers and the Sensex.